HIV/AIDS Clinical Trial
— EV06Official title:
A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection
The primary objective of the proposed phase I trial is to evaluate the safety and
tolerability of DNA-HIV-PT123 and AIDSVAX®B/E combination regimen. Though both DNA-HIV-PT123
and AIDSVAX®B/E and the combination of the two vaccines have been evaluated in humans and
have shown to be safe and well tolerated, this is the first time the combination regimen is
being evaluated in HIV-1 uninfected African populations with and without S. mansoni. The
secondary objective of the trial is to evaluate the effect of S. mansoni infection on the
immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX® B/E vaccine regimen.
Successful vaccination against most viruses requires efficient Th1 response. There is
evidence that helminth infections skew the host immune system of human and animals to
T-helper type 2 (Th2) and induce immunosuppression. Therefore, there is a potential that
helminth infected populations may not generate the desired immune responses to vaccines
designed to drive Th1-type and cytotoxic T-cell responses.
Furthermore, the influence of helminth infections on the development of protective antibody
responses remains unclear. Limited data in animal models suggests that worm infections
reduced efficacy of vaccines.
The proposed vaccine trial will generate safety, tolerability and immunogenicity data of a
vaccination regimen with simultaneous administration of a candidate HIV DNA vaccine
(DNA-HIV-PT123) and a gp120 protein vaccine (AIDSVAX®B/E). This will be the first HIV
vaccine trial to prospectively evaluate the impact of the S. mansoni infection on safety and
immune responses to HIV vaccines.
Status | Completed |
Enrollment | 72 |
Est. completion date | January 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. HIV-1 uninfected adults aged 18-45 years, as confirmed by a medical history, physical exam, and laboratory tests during screening 2. In 50% of study volunteers, positive for S. mansoni infection but negative for other helminth infections. 3. In 50% of study volunteers, negative for S. mansoni and other helminth infections 4. Willing to forgo treatment with praziquantel until after completion of week 26 visit in the trial. 5. Able and willing to provide written informed consent prior to screening 6. Aged 18 through 45 years on the day of first vaccination 7. Able and willing to complete screening (about 1 month) and available for the planned follow-up period (9months) 8. Willing to undergo HIV testing, risk reduction counselling, receive HIV test results and committed to maintaining low risk behaviour for the trial duration 9. If female of childbearing potential (not menopausal or sterilised), willing to use a non-barrier contraceptive method from screening through the end of the study. Acceptable contraceptive methods include hormonal contraceptives (injection, transdermal patch, or implant) and intrauterine device (IUD). 10. Willing to provide blood, urine and stool samples for laboratory examination Exclusion Criteria: 1. HIV-1 infection 2. Infection with other helminths 3. Symptomatic and asymptomatic malaria infection (presence of malaria parasites on thick blood smear) 4. Treatment with praziquantel in the past 3 months 5. S. mansoni egg count of>2000 eggs per gram of stool 6. Clinically significant acute or chronic illness at the time of randomization. 7. Any clinically relevant abnormality on history or examination 8. Use of immunosuppressive medication (other than inhaled or topical immunosuppressants) 9. Receipt of immunoglobulin within past 60 days 10. Abnormal laboratory values as specified below from blood collected within 28 days prior to randomization: 1. Hematology - Haemoglobin <9.0 g/dL or<5.59 mmol/L - Absolute Neutrophil Count (ANC): < 1000/mm3or < 1.0 x 109/L - Absolute Lymphocyte Count (ALC): = 500/mm3or = 0.5 x 109/L - Platelets: = 90,000 = 550,000/mm3or = 90 x 109 = 550 x 109/L 2. Chemistry - Creatinine: > 1. 1 x ULN - AST: >2.6 x ULN - ALT: >2.6 x ULN 3. Urinalysis: abnormal dipstick confirmed by microscopy - Protein 2+ or more - Blood 2+ or more (not due to menses) 11. Reported high-risk behaviour for HIV infection within 3 months prior to first vaccination, as defined by: - Unprotected sexual intercourse with a known HIV-infected person, a partner known to be at high risk of HIV infection or a casual partner - Unprotected sexual intercourse with more than one sexual partner - Engagement in sex work for money or drugs - Use of recreational drugs (e.g. marijuana) and/or weekly or more frequent alcohol use - Current or past STI 12. History or evidence of autoimmune disease. 13. Positive for Hepatitis B surface antigen (HbsAg), positive for antibodies to Hepatitis C virus (HCV) or active syphilis. 14. Receipt of blood or blood products within the previous 6 months 15. History of severe allergic reactions to any substance requiring hospitalization or emergency medical care (e.g. Steven-Johnson syndrome, bronchospasm or hypotension) 16. Prior or current participation in another investigational agent trial 17. Current anti-tuberculosis (TB) prophylaxis or therapy 18. If female, currently pregnant (positive serum or urine pregnancy test), planning to get pregnant in the next 9months or lactating 19. History or evidence of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may compromise the volunteer's safety or interfere with the evaluation of the safety or immunogenicity of the vaccine |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Uganda | Uganda Virus Research Institute - International AIDS Vaccine Initiative HIV Vaccine Program (UVRI-IAVI) | Entebbe | |
Uganda | Medical Research Council (MRC) /Uganda Virus Research Institute (UVRI) | Masaka |
Lead Sponsor | Collaborator |
---|---|
EuroVacc Foundation | Centre Hospitalier Universitaire Vaudois, International AIDS Vaccine Initiative, Medical Research Council, MRC/UVRI Uganda Research Unit on Aids |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of volunteers with local and systemic reactogenicity events during a 7 day follow up period after each vaccination | 7 days post each vaccination | Yes | |
Primary | Proportion of volunteers with adverse events during a 4 week follow up period after each vaccination | 4 weeks post each vaccination | Yes | |
Primary | Proportion of volunteers with abnormal laboratory parameters during a 4 week follow up period after each vaccination | 4 weeks post each vaccination | Yes | |
Primary | Proportion of volunteers with serious adverse events throughout the study period | Each participant will be followed for 9 months | Yes | |
Secondary | Proportion of volunteers with HIV-specific CD4+ and CD8+ T cell responses as assessed by IFN-g ELISpot and multiparameter flow cytometry (IFN-g TNF-a and IL-2) 2 weeks after the 2nd and 3rd vaccination | two weeks post 2nd and 3 vaccination | No | |
Secondary | Magnitude of HIV-specific CD4+ and CD8+ T cell responses as assessed by IFN-g ELISpot and multiparameter flow cytometry (IFN-g TNF-a and IL-2) 2 weeks after the 2nd and 3rd vaccination | two weeks post 2nd and 3 vaccination | No | |
Secondary | HIV-specific Env binding Antibody response 2 weeks after the 2nd and 3rd vaccination | two weeks post 2nd and 3 vaccination | No | |
Secondary | Magnitude and breadth of neutralizing antibody responses against tier 1 and tier 2 HIV-1 isolates 2 weeks after the 2nd and 3rd vaccination | two weeks post 2nd and 3 vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|
||
Completed |
NCT00722644 -
Cognitive Behavioral Stress Management for HIV+ Drug Abusers
|
Phase 1 |